Skip to main content

Table 3 Incidence and severity of post-ERCP pancreatitis according to the usage of nafamostat mesilate after matching

From: The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis

 

Nafmostat mesilate (n = 201)

Control (n = 106)

Total (N = 307)

P value

PEP (%)

35 (17.4)

11 (10.3)

46 (15.0)

0.168

 Mild (%)

30 (85.7)

5 (45.5)

35 (76.1)

0.021

 Moderate to severe (%)

5 (14.3)

6 (54.5)

11 (23.9)

 
  1. PEP post-ERCP pancreatitis